Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults

A Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of High-Dose Live Recombinant Canarypox ALVAC-HIV Vaccine (vCP1452) in Healthy, HIV-1 Uninfected Adult Participants

The purpose of this study is to see if the experimental vaccine, ALVAC-HIV (vCP1452) is safe and to study how the immune system responds to the vaccine. This trial is designed to determine whether a higher vaccine dose (6 times the usual dose) will elicit a higher immune response.

As of May 2001, over 200 people received the ALVAC-HIV (vCP1452) vaccine at the lower dose. The higher dose of the vaccine to be used in this study has not been given to humans previously. High doses of a similar vaccine have been given to a few people without serious side effects. In a recent study done in mice, higher doses of ALVAC-HIV produced stronger immune responses. It is possible that the doses of ALVAC-HIV given to humans are below the amount needed for the maximum immune response. Because the exact relationship between an increased immune response and its effectiveness in preventing HIV infection is uncertain, the HVTN will use the highest dose that can be manufactured.

Descripción general del estudio

Estado

Terminado

Descripción detallada

To date, adverse reactions to immunization with the various ALVAC-HIV candidate vaccines, including ALVAC-HIV (vCP1452), have been similar to those observed in healthy adults who have received other licensed vaccines of similar types. In a previous trial, even high doses of recombinant ALVAC vaccine were well tolerated in a group of participants that were significantly immunocompromised. In a recent study done in mice concerning dose escalation using the ALVAC-HIV vectors, the data demonstrated more robust immune responses with higher doses of ALVAC-HIV (vCP1452) in mice. It is certainly possible that the doses of ALVAC-HIV given to humans are well below the amount needed for a maximal cytotoxic T lymphocyte (CTL) response. As the predictive value of a CTL response is at present unknown with respect to its efficacy in preventing or ameliorating HIV acquisition or infection, the HVTN will utilize the highest dose that can be currently manufactured.

All study products are to be administered intramuscularly. Participants will receive 1 of 3 injections. Group A will receive a high dose of vaccine, group B will receive a low dose of vaccine, and group C will receive a placebo. Participants are inoculated at 4 time points. Assessment of product safety includes clinical observation, monitoring of hematological, chemical, and immunologic parameters, and a social harms questionnaire. Safety will be evaluated by monitoring of participants for local and systemic adverse reactions during the course of the trial. Participants will be monitored longitudinally for HIV-specific serologic and cellular immune responses.

Tipo de estudio

Intervencionista

Inscripción (Actual)

110

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • Alabama Vaccine CRS
    • California
      • San Francisco, California, Estados Unidos, 94102
        • San Francisco Vaccine and Prevention CRS
      • San Francisco, California, Estados Unidos
        • UCSF, Gen. Clinical Research Ctr., Mt. Zion Hosp.
    • Maryland
      • Baltimore, Maryland, Estados Unidos
        • Project Brave HIV Vaccine CRS
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham and Women's Hosp. CRS
      • Boston, Massachusetts, Estados Unidos, 02115
        • Fenway Community Health Clinical Research Site (FCHCRS)
    • Missouri
      • Saint Louis, Missouri, Estados Unidos, 63110
        • Saint Louis Univ Health Sciences Ctr
    • New York
      • New York, New York, Estados Unidos, 10021
        • NY Blood Ctr./Union Square CRS
      • Rochester, New York, Estados Unidos, 14642
        • Univ. of Rochester HVTN CRS
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02906
        • Miriam Hospital's HVTU
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Vanderbilt Vaccine CRS
    • Virginia
      • Annandale, Virginia, Estados Unidos
        • Infectious Diseases Physicians, Inc.
    • Washington
      • Seattle, Washington, Estados Unidos, 98109
        • FHCRC/UW Vaccine CRS

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 60 años (Adulto)

Acepta Voluntarios Saludables

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

Participants may be eligible for this study if they:

  • Are between the ages of 18 and 60.
  • Are in good general health.
  • Have a CD4 count of 400 or more cells/mm3.
  • Do not have hepatitis C or active hepatitis B.
  • Have had a negative HIV blood test within 8 weeks prior to enrollment.
  • Use approved methods of contraception.
  • Have access to a participating site and are available for follow-up for 18 months.
  • Complete a questionnaire evaluating the participant's understanding of the study prior to enrollment.
  • Give written informed consent.

Exclusion Criteria

Participants may not be eligible for this study if they:

  • Are pregnant or breast-feeding.
  • Have received a live vaccine within 30 days prior to enrollment.
  • Have received a killed vaccine or allergy treatment with injections within 14 days prior to study vaccine.
  • Have used experimental research agents within 30 days prior to enrollment.
  • Have received HIV-1 vaccines or placebo in a previous HIV vaccine trial.
  • Have received blood products 120 days before HIV screening.
  • Have received immunoglobulin 60 days before HIV screening.
  • Have a history of serious harmful reactions to vaccines.
  • Have a history of disease of the immune system.
  • Have a history of cancer, unless it has been surgically removed and in the estimate of the investigator is not likely to happen again during the study period.
  • Are using or have used (within past 6 months) drugs that interfere with the immune system.
  • Have a history of type I or type II diabetes.
  • Have thyroid disease.
  • Have unstable asthma.
  • Are currently taking preventive anti-TB therapy.
  • Have a seizure disorder.
  • Have a bleeding disorder that was diagnosed by a physician.
  • Have had their spleen removed.
  • Have angioedema with serious episodes.
  • Have active syphilis.
  • Have hypertension.
  • Have mental problems that would interfere with the protocol.
  • Have any other problems that, in the judgment of the investigator, would interfere with the study.
  • Have a body mass index less than 20.
  • Are allergic or sensitive to egg products.
  • Have active tuberculosis.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Enmascaramiento: Doble

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Silla de estudio: Paul Goepfert

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Finalización del estudio (Actual)

1 de diciembre de 2005

Fechas de registro del estudio

Enviado por primera vez

29 de noviembre de 2001

Primero enviado que cumplió con los criterios de control de calidad

29 de noviembre de 2001

Publicado por primera vez (Estimar)

30 de noviembre de 2001

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de octubre de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

13 de octubre de 2021

Última verificación

1 de octubre de 2021

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Infecciones por VIH

Ensayos clínicos sobre ALVAC(2)120(B,MN)PNB (vCP1452)

3
Suscribir